Cargando…

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment

BACKGROUND: There is limited information on neurochemical markers being used to support and monitor the affection of motoneurons in patients with spinal muscular atrophy (SMA). The objective of this study was to examine neurochemical markers in cerebrospinal fluid (CSF) under treatment with the anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wurster, Claudia D., Günther, René, Steinacker, Petra, Dreyhaupt, Jens, Wollinsky, Kurt, Uzelac, Zeljko, Witzel, Simon, Kocak, Tugrul, Winter, Benedikt, Koch, Jan C., Lingor, Paul, Petri, Susanne, Ludolph, Albert C., Hermann, Andreas, Otto, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535708/ https://www.ncbi.nlm.nih.gov/pubmed/31205491 http://dx.doi.org/10.1177/1756286419846058

Ejemplares similares

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen
por: Garofalo, M., et al.
Publicado: (2023)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
por: Mix, Lucas, et al.
Publicado: (2021)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen
por: Johannsen, Jessika, et al.
Publicado: (2021)

Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

Evaluator Training and Reliability for SMA Global Nusinersen Trials(1)
por: Glanzman, Allan M., et al.
Publicado: (2018)

Response of plasma microRNAs to nusinersen treatment in patients with SMA
por: Zaharieva, Irina T., et al.
Publicado: (2022)

Correction: Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen
por: Vidovic, Maximilian, et al.
Publicado: (2023)

NFL is a marker of treatment response in children with SMA treated with nusinersen
por: Olsson, Bob, et al.
Publicado: (2019)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients
por: Bonanno, Silvia, et al.
Publicado: (2020)

Muscle quantitative MRI in adult SMA patients on nusinersen treatment: a longitudinal study
por: Gallone, Annamaria, et al.
Publicado: (2022)

Muscle MRI in two SMA patients on nusinersen treatment: A two years follow-up
por: Barp, Andrea, et al.
Publicado: (2020)

Successful weaning from mechanical ventilation in a patient with SMA type 1 treated with nusinersen
por: Lee, Jiwon, et al.
Publicado: (2021)

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients
por: Pane, Marika, et al.
Publicado: (2021)

Effect of the COVID-19 Pandemic on Children With SMA Receiving Nusinersen: What Is Missed and What Is Gained?
por: Agosto, Caterina, et al.
Publicado: (2021)

Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months
por: De Wel, Bram, et al.
Publicado: (2022)

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
por: Scheijmans, Féline E. V., et al.
Publicado: (2022)

Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study
por: Walter, Maggie C., et al.
Publicado: (2019)

Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
por: Pechmann, Astrid, et al.
Publicado: (2018)

Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review
por: Ali, Imran, et al.
Publicado: (2019)

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice
por: Kordala, Anna J, et al.
Publicado: (2023)

Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy – A pilot study
por: Kruse, Teresa, et al.
Publicado: (2020)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

Assessment of Bulbar Function in Adult Patients with 5q-SMA Type 2 and 3 under Treatment with Nusinersen
por: Brakemeier, Svenja, et al.
Publicado: (2021)

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
por: Coratti, Giorgia, et al.
Publicado: (2021)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review
por: Jesse, Sarah, et al.
Publicado: (2009)

Successful weaning from the invasive respiratory support after nusinersen treatment in a child with SMA type 1: A case report
por: Pan, Meiling, et al.
Publicado: (2023)

Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis
por: Wohnrade, Camilla, et al.
Publicado: (2023)

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study
por: Audic, Frédérique, et al.
Publicado: (2020)

Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model
por: Berciano, María T., et al.
Publicado: (2020)

CSF SerpinA1 in Creutzfeldt–Jakob disease and frontotemporal lobar degeneration
por: Abu‐Rumeileh, Samir, et al.
Publicado: (2020)

Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
por: Cordts, Isabell, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_supme1l1q34in0d75eth60k6f7